BioPorto (BIOPOR) Status Update summary

Strategic direction and growth aspirations

• Launched the "Forward" plan, a three-year strategy to build market adoption, capture high growth, and expand the addressable market for kidney health biomarkers.

• Aims to reach over 60 active US hospitals by 2026, 100+ globally by 2027, and 170+ by 2028 through increased adoption and clinical validation.

• Focuses on expanding into new patient segments and clinical settings beyond intensive care units via product development and partnerships.

• Strategic partnerships with instrument manufacturers are key to accelerating product adoption in laboratories.

Financial targets and funding needs

• Targets positive cash flow in the second half of 2027, with FY 2028 revenue between DKK 150-200 million and an adjusted EBITDA margin of at least 15%.

• Requires DKK 60-70 million in additional funding to reach cash flow positivity, with financing options under evaluation.

• Updated aspirations replace previous targets, extending the timeline for cash flow positivity and revenue milestones.

Commercialization and market expansion

• US hospital adoption is increasing, supported by research use and FDA clearance for pediatric use.

• Plans to leverage US market experience for targeted European expansion, with EU IVDR certification expected in 2027.

• Market penetration will focus on both pediatric and adult segments, anticipating enhanced clinical guidelines to drive adoption.